Ashley L. Lennox

机构：Geron (United States), Gilead Sciences (United States)

发表论文 8 篇 · 总被引 43 次 · h-index 3

代表论文

• Imetelstat, a novel, first‐in‐class telomerase inhibitor: Mechanism of action, clinical, and translational science (2024 · Clinical and Translational Science · 被引 31)
• Population pharmacokinetics of imetelstat, a first‐in‐class oligonucleotide telomerase inhibitor (2024 · CPT Pharmacometrics & Systems Pharmacology · 被引 6)
• Low Proarrhythmic Risk of Imetelstat, a Novel Oligonucleotide Telomerase Inhibitor: A Translational Analysis (2025 · Clinical and Translational Science · 被引 3)
• P410 Liver involvement in myotubular and centronuclear Myopathy: data from the MTM & CNM patient registry (2023 · Neuromuscular Disorders · 被引 2)
• Clinical outcomes and safety in patients with lower‐risk myelodysplastic syndromes treated with imetelstat: Substudy of the phase 3 IMerge trial (2025 · British Journal of Haematology · 被引 1)
• Initial Results from the QTc Substudy of the IMerge Phase 3 Trial Demonstrate Clinically Meaningful Efficacy, Manageable Safety, and Absence of Proarrhythmic Risk in Patients with Lower-Risk Myelodysplastic Syndromes Who Received Prior Therapies Beyond Erythropoiesis Stimulating Agents (2024 · Blood · 被引 1)